在接受增强型蛋白酶抑制剂治疗的病毒血症HIV感染患者中维持降低的病毒适应性和CD4反应

Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.

作者信息

Grant Philip, Taylor Jonathan, Cain Pat, Short William, Gallant Joel, Farthing Charles, Thal Gary, Coakley Eoin, Zolopa Andrew

机构信息

Division of Infectious Diseases and Geographic Medicine, Stanford University, Palo Alto, California 94305-5107, USA.

出版信息

Clin Infect Dis. 2009 Mar 1;48(5):680-2. doi: 10.1086/597008.

DOI:10.1086/597008

PMID:19191657

Abstract

When fully suppressive regimens are not available, incompletely suppressive regimens also provide immunologic benefits. In this study, with stable background therapy, human immunodeficiency virus (HIV)-infected patients who were randomized to receive atazanavir or boosted atazanavir, compared with those who continued boosted protease inhibitor therapy, maintained similar virologic and immunologic control, resistance-mutation patterns, and replication capacities with reduced use of lipid-lowering medication.

摘要

当无法获得完全抑制性治疗方案时，不完全抑制性治疗方案也能带来免疫学益处。在本研究中，在稳定的背景治疗下，与继续接受增强型蛋白酶抑制剂治疗的患者相比，随机接受阿扎那韦或增强型阿扎那韦治疗的人类免疫缺陷病毒（HIV）感染患者在减少使用降脂药物的情况下，维持了相似的病毒学和免疫学控制、耐药突变模式及复制能力。